Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03515-3